Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Status:
Completed
Trial end date:
2004-07-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of AMG 531 (romiplostim),
a novel thrombopoiesis-stimulating peptibody, and its effect on platelet counts in adults
with immune thrombocytopenic purpura.